Appendix SI

SUPPLEMENTAL MATERIALS & METHODS AND RESULTS

Material

Subject sample and blood collection. Samples were obtained from cutaneous T-cell lymphoma patients from the Arizona Cancer Center (AZCC) and the Dana Farber Cancer Institute (DFCI), Harvard Medical School, Specialized Cutaneous Oncology Clinic. These subjects were originally recruited for a study correlating serum markers with disease stage and processed as described (S1). Healthy donors were recruited at Boston University Medical Center (BUMC). Specific information regarding demographics and characteristics of the disease were recorded prospectively. Characteristics of pruritus were not recorded prospectively. All protocols and procedures have been approved by the IRB committees at the BUMC, AZCC and the DFCI.

ELISAs. ELISAs were performed using the Quantikine Human SP Immunoassay kit (R&D Systems, Inc., Minneapolis, MN), according to manufacturer’s protocols. The optical density at 450-570 nm was measured with a VMax kinetic Microplate reader (Molecular Devices, Sunnyvale, CA). The final concentrations of SP in plasma were calculated based on standard curve values.

Immunohistochemistry on slide-mounted sections. Following approval by the IRB at Boston University, paraffin-embedded skin biopsies from 17 CTCL-mycosis fungoides (CTCL-MF) patients, normal skin, and from scars obtained from otherwise healthy individuals, were obtained. 11 of the 17 CTCL-MF samples had accessible medical records that were reviewed to determine if the skin lesion sampled had definitive evidence of pruritus at the time of biopsy. Five of 17 had definitive evidence of active pruritus in the lesion biopsied at the time of biopsy. Of the remaining 12 CTCL-MF biopsies, active but undocumented pruritus may have existed, as 66% to 88% of CTCL-MF patients have reported pruritus {Vij, 2012 #17}. All samples were sectioned at 4 µm, deparaffinized with HistoClear solution (National Diagnostics, Atlanta, GA), rehydrated, antigen unmasked (95 oC for 40 min in pH=9.0 buffer from Vector Labs, Burlingame, CA), peroxidase quenched, incubated in primary antibody at +4 oC overnight and secondary antibody for 1 h at room temperature. Enzymatic detection used either tyramide-Alexa Fluor 488 or tyramide-Alexa Fluor 568 (Life Technologies). For double-labeling experiments, residual HRP activity was inactivated by 30 min incubation in 27% H2O2/1XPBS/0.25% triton-X solution. Sections were blocked again for 1 h, and the antibody staining procedure repeated.

Primary antibodies. C-terminus-detecting primary NK1R antibody (detects full-length NK1R only) used for the experiments in this paper: rat-anti-human NK1R (Immunostar, #20060; 1:1000). This well-characterized antibody is raised against a peptide sequence at the carboxy C-terminus of rat NK1 receptor (residues 393–407: KTMTESSSYSNMLA). This antiserum detected NK1R only in a cell line transfected with a chimeric NK1 receptor construct but not vector alone and to give an expression pattern in rat brain that highly correlated with both 125I-labeled NK1 receptor-binding sites and autoradiographic localization of 3H-substance P (S2). Immunolabeling was absent in NK1R-deficient knock-out mice (S2). Preadsorption with the immunizing peptide abolished immunolabeling in rat and normal human brain sections and Western blots of rat brain tissue (antibody data sheet, Immunostar) (S2).

N-terminus-detecting primary NK1R antibody (would detect both full-length and truncated NK1R) used only in preliminary optimization trials, including reproducing the conditions of Remröd et al. (S3): Novus Biologicals, NB300-119. Other non-NK1R primary antibodies used: mouse-anti-human CD3 (clone F7.2.38, DAKO, M7254; 1:875), and mouse anti-mast cell tryptase (clone AA1, Abserotec, MCA1438T; 1:200).

Secondary antibodies: Impress (Vector Labs) for CD3 and NK1R or donkey anti-mouse dyl488 (Jackson Immunoresearch, West Grove, PA).

For peptide blocking experiments, the primary antibody solution was pre-incubated 16 hours at +4°C with the immunizing peptide (Immunostar, #24340) at 20 µg/ml.

Immunohistochemistry on cytosin preparations. Cytospins of blood cells were prepared and stained with immunohistochemical buffers and antibodies using the same antibody reagents and concentrations as per the paraffin sections above. The nuclei were counterstained with SlowFade Gold anti-fade reagent with DAPI (Invitrogen Molecular Probes, Eugene, OR). All image analyses were performed with Zeiss Axioskop 40 microscope (Carl Zeiss MicroImaging, LLC., Thornwood, NY), using the Axiosvision Rel. 4.6 software (×400 magnified).

Immunohistochemistry on free-floating sections. 50 µM thick rolls were cut from 9 of the 17 randomly selected CTCL-MF paraffin blocks, deparaffinized by standard procedures and subjected, without antigen retrieval, to triple-label free floating immunohistochemistry as described (2) using guinea pig anti-substance P (1:12,000; Neuromics, Edina, MN), mouse-anti-human CD3 (clone F7.2.38, DAKO, M7254; 1:875), and rabbit anti-protein gene product 9.5 (1:18,000; Abserotec, Raleigh, NC) as primaries; using donkey anti-guinea pig, anti-rabbit HRP, or anti-mouse HRP (Jackson Immunoresearch, West Grove, PA) as secondaries; and tyramide amplification (Life Technologies).

Quantitation of nerve length in free-floating sections. For each specimen, two or three 2.4 mm wide fields containing SP+ nerves were selected, each corresponding to a different tissue piece from a bi- or tri-sected biopsy section. Images were acquired at 4 µm intervals throughout the depth of the specimen for the entire 2.4 mm wide field using a ×20 lens (Z-series), separately for each fluorescent signal. In all cases, the imaging field had at its most rostral edge, the stratum corneum and extended to a depth of at least 200 µm beneath the dermal-epidermal junction visible as endogenous autofluorescence of keratinocytes. Image J (NIH) and Neuron J (S4) software were used to quantitate nerve lengths as previously described (2). JMP10 statistical software was used to calculate percentages of nerve fibers, presented as median with 25% and 75% quartiles. Statistical analyses were performed with one-way ANOVA analysis and either Dunnett’s, or Mann-Whitney post-test. p < 0.05 was considered significant.

Results

We performed preliminary experiments to optimize immunohistochemical staining of both the C-terminus-directed and N-terminus-directed NK1R primary antibodies. The expression pattern generated by the C-terminus antibody (F-NK1R) correlated with findings from previously reported studies that used either biotinylated or I-125-conjugated SP on frozen sections or used immunohistochemistry on formalin-fixed sections with an antibody targeting the N-terminus of the NK1R (S1, S3, S5, S6). In normal skin, surgically-induced scars, and in five randomly selected CTCL-MF skin samples, we confirmed the dermal fl-NK1R expressing cells were mast cells, using double-immunohistochemical labeling with mast-cell tryptase (Fig. S1 and data not shown). Fl-NK1R staining was abolished when the C-terminal primary antibody was omitted or when this primary antibody was pre-incubated with the immunizing peptide in skin (Fig. S1) and in cytospin samples (Fig. S2). These experiments confirmed the specificity of the staining in human skin and blood samples. The N-terminus antibody

Acta Derm Venereol 95
produced only non-specific staining (data not shown). Therefore, only the C-terminus antibody was used for subsequent immunohistochemical detection of fl-NK1r.

SUPPLEMENTAL REFERENCES